Hostname: page-component-848d4c4894-xm8r8 Total loading time: 0 Render date: 2024-07-02T11:21:22.856Z Has data issue: false hasContentIssue false

Antidepressant treatment in premenstrual dysphoric disorder, case report

Published online by Cambridge University Press:  01 September 2022

M. Garcia Moreno*
Affiliation:
HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA, Psychiatry, MADRID, Spain
A. De Cos Milas
Affiliation:
HOSPITAL UNIVERSITARIO DE MÓSTOLES, Psychiatry, MADRID, Spain
L. Beatobe Carreño
Affiliation:
HOSPITAL UNIVERSITARIO DE MÓSTOLES, Psychiatry, MADRID, Spain
M.B. Poza Cano
Affiliation:
HOSPITAL UNIVERSITARIO EL ESCORIAL, Psychiatry, MADRID, Spain
A. Izquierdo De La Puente
Affiliation:
HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA, Psychiatry, MADRID, Spain
P. Del Sol Calderón
Affiliation:
Hospital Universitario Puerta de Hierro, Psiquiatría Infanto-juvenil, Madrid, Spain
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Premenstrual dysphoric disorder (PMDD) is included for the first time in the last edition of DSM within affective disorders. It is necessary that 5 of a list of 11 symptoms (lability, irritability, depressed mood, anxiety, lethargy, being out of control or physical symptoms among others) appear in the majority of menstrual cycles but must be only present during the week before menstruation improving after its onset. It has a prevalence of 1,8-5,8% and it is associated to significant functional impairment. SSRIs are indicated as first-line treatment in severe symptoms.

Objectives

To review about premenstrual dysphoric disorder and its psychopharmacological treatment.

Methods

We carry out a literature review about premenstrual dysphoric disorder, accompanied by a clinical description of one patient treated with sertraline.

Results

44 years old female referred to our outpatient mental health service due to anxious and depressive symptoms. She had presented abdominal pain, anxiety, obsessive thoughts, sadness, emotional lability, apahty, anergy, uncontrolled impulse, irritability and vociferous attitude with verbal agressiveness only the week before menstruation during several years. These symptoms interfered negatively in her relationships. We started sertraline treatment with ad integrum clinical recovery after two menstrual cycles. 6 months later we indicated to take sertraline only the week before menstruation, maintaining stability.

Conclusions

1) It is important to consider premenstrual dysphoric disorder as a possible diagnosis in women with premenstrual discomfort symptoms. 2) It might be consider as a depressive disorder. 3) Antidepressant treatment should be considered in women with disabling symptoms.

Disclosure

No significant relationships.

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.